First Coast Mohs has been acquired by AQUA Dermatology
Dermatology and skin cancer specialist First Coast Mohs has partnered with AQUA Dermatology.
First Coast Mohs offers Mohs surgery, surgical and medical dermatology, dermatopathology, cosmetic and laser treatments, electrolysis and other aesthetic services from four state-of-the-art facilities in metro Jacksonville, Florida. The practice features seven clinicians, including two Mohs surgeons, two board certified dermatologists and three Advanced Practice Providers. First Coast Mohs was founded in 2002 by Dr. Scott Warren, who will continue to lead the practice following the transaction.
AQUA Dermatology, backed by Gryphon Investors and GTCR, is the largest dermatology practice in the southeastern United States with over 110 locations and 250 providers. For more than 25 years, the company has treated patients of all ages suffering from skin diseases, acne, sun damage, skin cancer and vein health issues, as well as those seeking cosmetic and plastic surgery. With First Coast Mohs, AQUA Dermatology now has 78 locations in Florida.
Oaklins Heritage in Jacksonville served as the intermediary and exclusive financial advisor to the seller in this transaction.
Dr. Scott Warren
Owner, First Coast Mohs
Contáctese con el equipo de la transacción
Transacciones relacionadas
MEDIK Hospital Design Group has been acquired by STERIS
The private shareholders of MEDIK Hospital Design Group have sold their shares to STERIS plc. Together, MEDIK and STERIS will expand their offerings for hospitals and ambulatory surgery centers worldwide. MEDIK’s solutions ideally complement STERIS’ existing portfolio, enabling the combined group to strengthen its position as a leading provider of turnkey room solutions in surgical and IPT environments. The MEDIK management team will actively support the next phase of growth.
Conozca másbioXXmed AG has sold Rancoderm GmbH to Rose Investment- und Beteiligungs AG
Rancoderm GmbH has been acquired by Rose Investment- und Beteiligungs AG to secure the funding required for the final development and market approval of its medical device DermaPro. The acquisition will enable Rancoderm to bring DermaPro to market readiness and launch it as a certified medical product for broad distribution.
Conozca másBanook, backed by Motion Equity, has acquired Fluidda
Banook Group has acquired Fluidda NV, marking a strategic expansion into advanced in-silico trials and respiratory disease modeling. Combining Banook’s expertise in cardiac safety and clinical data services with Fluidda’s AI-driven respiratory analytics creates a powerful, integrated platform. This deal strengthens Banook’s position in the contract research organization (CRO) sector, offering pharmaceutical clients broader, technology-enabled solutions to drive drug development and reduce costs.
Conozca más